Evelo Biosciences Sees Unusually Large Options Volume (NASDAQ:EVLO)

Evelo Biosciences, Inc. (NASDAQ:EVLO) was the target of some unusual options trading on Wednesday. Stock investors acquired 1,885 put options on the company. This is an increase of 1,101% compared to the average daily volume of 157 put options.

Institutional Investors Weigh In On Evelo Biosciences

A number of institutional investors have recently modified their holdings of EVLO. Shay Capital LLC acquired a new stake in shares of Evelo Biosciences in the fourth quarter valued at $30,000. Barclays PLC grew its stake in Evelo Biosciences by 654.2% during the 4th quarter. Barclays PLC now owns 22,641 shares of the company’s stock worth $36,000 after purchasing an additional 19,639 shares in the last quarter. Walleye Capital LLC acquired a new position in Evelo Biosciences during the 1st quarter worth $38,000. Boothbay Fund Management LLC acquired a new position in Evelo Biosciences during the 4th quarter worth $85,000. Finally, Man Group plc acquired a new position in Evelo Biosciences during the 4th quarter worth $85,000. 0.31% of the stock is owned by institutional investors and hedge funds.

Evelo Biosciences Stock Performance

Shares of NASDAQ EVLO opened at $0.04 on Thursday. Evelo Biosciences has a twelve month low of $0.03 and a twelve month high of $13.93. The stock has a fifty day simple moving average of $0.05 and a 200-day simple moving average of $0.43. The stock has a market capitalization of $834,171.00, a PE ratio of 0.00 and a beta of 2.03.

Evelo Biosciences Company Profile

Evelo Biosciences, Inc, a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis.